stockrowMerck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −130.7%
- Free cash flow
- +77.0%
- Total debt
- +50.4%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Gross margin
Merck & Co., Inc.'s gross margin over the twelve months to 30 September 2026 was 71.8%, down 3.0 percentage points from fiscal 2025 (74.8%). Over the past ten years it has ranged from 62.2% (fiscal 2015) to 76.3% (fiscal 2024); the current reading is higher than 91% of that period. That is in line with the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 74.8% | (1.52) |
| FY2024 | 76.3% | 3.15 |
| FY2023 | 73.2% | 2.54 |
| FY2022 | 70.6% | (1.39) |
| FY2021 | 72.0% | 4.82 |
| FY2020 | 67.2% | (2.09) |
| FY2019 | 69.3% | 1.23 |
| FY2018 | 68.1% | 0.24 |
| FY2017 | 67.8% | 3.07 |
| FY2016 | 64.8% | 2.56 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 73.0% | (0.59) |
| Jun 2026 | 73.5% | (0.70) |
| Mar 2026 | 74.2% | 8.09 |
| Dec 2025 | 66.2% | (11.54) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG compare | 74.9% |
| ABBV AbbVie Inc. compare | 73.7% |
| PFE Pfizer Inc. compare | 73.4% |
| MRK Merck & Co., Inc. | 71.8% |
| AMGN Amgen Inc. compare | 70.9% |
| JNJ Johnson & Johnson compare | 67.6% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement